Physician profile
Michael Post
NPI 1598151664
$7,499.95
in general payments reported to CMS, 2019-2025
46 companies · $2,444 in 2025
The $2,444 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.50 · 2022: $577 · 2023: $1,890 · 2024: $2,576 · 2025: $2,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,813 · Education: $97.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,812.58 |
| Education | $97.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,074.40 | 2022-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $1,020.86 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Insmed, INC. | $476.39 | 2022-2025 | Arikayce |
| Genzyme Corporation | $377.08 | 2022-2025 | |
| Harmony Biosciences LLC | $307.99 | 2023-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.74 | 2022-2025 | Ofev, Jascayd, Stiolto Respimat |
| Axsome Therapeutics, INC. | $238.92 | 2023-2025 | Sunosi |
| Mylan Specialty L.P. | $226.91 | 2023-2024 | Yupelri |
| Verona Pharma, INC. | $217.74 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $199.76 | 2023-2025 | Aralast |
| Abbvie INC. | $196.51 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $194.39 | 2024-2025 | Acthar |
| United Therapeutics Corporation | $174.66 | 2023-2025 | Tyvaso, Tyvaso |
| Pulmonx Corporation | $171.31 | 2024-2025 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Philips North America LLC | $145.25 | 2022-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $140.33 | 2024-2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $139.19 | 2023-2025 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $135.69 | 2019-2025 | Dupixent |
| Amgen INC. | $134.09 | 2024-2025 | Tezspire, Tavneos |
| Grifols USA, LLC | $129.53 | 2025 | Prolastin-C Liquid |
| Ani Pharmaceuticals, INC. | $108.40 | 2023-2024 | Purified Cortrophin Gel |
| Zoll Respicardia, INC. | $106.52 | 2024-2025 | Remede System |
| Alexion Pharmaceuticals, INC. | $104.41 | 2024-2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $100.96 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $98.90 | 2023-2024 | Xarelto |
| Vifor Pharma, INC. | $96.95 | 2024-2025 | Zemaira, Veltassa |
| Electromed, INC. | $91.24 | 2024-2025 | Smartvest |
| Viatris Specialty LLC | $79.95 | 2025 | Yupelri |
| Sanofi-Aventis U.S. LLC | $78.99 | 2024 | |
| Genentech USA, INC. | $76.44 | 2023-2024 | Xolair |
| Merck Sharp & Dohme LLC | $75.00 | 2022-2024 | Zerbaxa, Recarbrio |
| Avadel Cns Pharmaceuticals, LLC | $73.75 | 2023-2024 | Lumryz |
| E.R. Squibb & Sons, L.L.C. | $64.75 | 2023-2024 | Eliquis |
| Olympus Corporation of The Americas | $60.00 | 2024 | |
| Tactile Systems Technology INC | $46.76 | 2024 | Entre Plus, Flexitouch Plus |
| Resmed Corp | $40.55 | 2024-2025 | |
| Abiomed | $40.06 | 2025 | |
| Pfizer INC. | $24.70 | 2025 | |
| Biomerieux INC | $24.60 | 2023 | |
| La Jolla Pharmaceutical Company | $24.24 | 2024 | Giapreza |
| Idorsia Pharmaceuticals US INC | $22.30 | 2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $19.29 | 2025 | |
| Baxter Healthcare | $18.66 | 2023 | Hillrom - Life 2000 Ventilation System |
| Paratek Pharmaceuticals, INC. | $16.80 | 2024 | Nuzyra |
| Optinose US, INC. | $15.67 | 2025 | |
| Inogen, INC. | $14.32 | 2023 | Inogen One G3 Oxygen Concentrator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Post listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.